Dicerna Pharmaceuticals (DRNA) & Clovis Oncology (CLVS) Financial Comparison

Clovis Oncology (NASDAQ:CLVS) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Volatility and Risk

Clovis Oncology has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500.

Profitability

This table compares Clovis Oncology and Dicerna Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Clovis Oncology -382.83% -94.28% -38.02%
Dicerna Pharmaceuticals -1,642.81% -97.39% -61.25%

Earnings & Valuation

This table compares Clovis Oncology and Dicerna Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Clovis Oncology $55.51 million 25.34 -$346.39 million ($5.12) -5.22
Dicerna Pharmaceuticals $2.28 million 359.20 -$60.04 million ($3.66) -3.62

Dicerna Pharmaceuticals has lower revenue, but higher earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Clovis Oncology and Dicerna Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clovis Oncology 0 3 11 0 2.79
Dicerna Pharmaceuticals 0 2 6 0 2.75

Clovis Oncology presently has a consensus price target of $75.85, suggesting a potential upside of 183.88%. Dicerna Pharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 43.40%. Given Clovis Oncology’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Clovis Oncology is more favorable than Dicerna Pharmaceuticals.

Institutional & Insider Ownership

74.6% of Dicerna Pharmaceuticals shares are held by institutional investors. 10.2% of Clovis Oncology shares are held by company insiders. Comparatively, 19.9% of Dicerna Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply